Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
Details : Company announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001able to rapidly and effectively restore coagulation in the presence of FXa DOAC, the Trial will assess safety, tolerability, PK and PD.
Product Name : VMX-C001
Product Type : Enzyme
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Ysios Capital
Deal Size : $36.6 million
Deal Type : Series B Financing
Details : Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.
Product Name : VMX-C001
Product Type : Enzyme
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Ysios Capital
Deal Size : $36.6 million
Deal Type : Series B Financing
Reset All
